News & Updates

The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.

Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.

Among fixed-dose combinations of inhaled corticosteroids/long-acting beta-2-adrenergic agonists (ICS/LABA), the newer combinations of fluticasone furoate/vilanterol (FF/VI) and fluticasone propionate/formoterol (FP/FORM) are associated with increased treatment persistence and lead to fewer exacerbations among patients with asthma, as shown in a study.

In the phase II/III EPIC-HR* trial, the novel oral antiviral nirmatrelvir-ritonavir reduced the risk of progression of COVID-19 to severe disease, as well as viral load, in symptomatic, high-risk, unvaccinated nonhospitalized adults confirmed to have SARS-CoV-2 infection.